The recent pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in unprecedented morbidity and mortality worldwide. The host cells use a number of pattern recognition receptors (PRRs) for early detection of coronavirus infection, and timely interferon secretion is highly effective against SARS-CoV-2 infection. However, the virus has developed many strategies to delay interferon secretion and disarm cellular defense by intervening in interferon-associated signaling pathways on multiple levels. As a result, some COVID-19 patients suffered dramatic susceptibility to SARS-CoV-2 infection, while another part of the population showed only mild or no symptoms. One hypothesis suggests that functional differences in innate immune integrity could be the key to such variability. This review tries to decipher possible interactions between SARS-CoV-2 proteins and human antiviral interferon sensors. We found that SARS-CoV-2 actively interacts with PRR sensors and antiviral pathways by avoiding interferon suppression, which could result in severe COVID-19 pathogenesis. Finally, we summarize data on available antiviral pharmaceutical options that have shown potential to reduce COVID-19 morbidity and mortality in recent clinical trials.
Off‐label use of biologic therapies in patients with pediatric inflammatory bowel disease (IBD) has seen an increase in utilization. In this paper, we review the current state of off‐label therapies in the pediatric IBD population. Real‐world use of ustekinumab (UST), vedolizumab (VDZ), upadacitinib (UPA), tofacitinib, and ozanimod in the adult population could prove positive outcomes in the pediatric population. Established off‐label therapies inch closer to comparable safety, efficacy, and outcomes in pediatric IBD use. Outcomes and use of newer biologic therapies in patients with pediatric IBD have improved with increased rates of steroid‐free clinical remission (SFCR). Novel therapies, including Janus kinase (JAK) inhibitors and sphingosine‐1‐phosphate receptor (S1Pr) modulators, require further studies but could also prove effective.
Phagocytosis, the process by which immune cells ingest and eliminate invading pathogens, is essential for host defense. During this process, phagosomes mature through the recruitment of several effector proteins, such as V-ATPases, proteases, and other enzymes, to effectively degrade the pathogen they contain. These maturation events are thought to be regulated by phosphoinositide transitions, which facilitate phagosome-lysosome fusion. The evolutionarily conserved COMMD/CCDC22/CCDC93 (CCC) complex regulates endosomal recycling and has been identified on phagosomes. Nevertheless, its role in phagosome maturation has not been previously demonstrated. Here, we show that the CCC complex is essential for efficient bacterial clearance by bone marrow-derived macrophages (BMDMs) and the temporal remodeling of phagosomal protein composition. We further reveal that the CCC complex regulates phagosome-lysosome fusion and identify excessive phosphatidylinositol-3-phosphate (PI(3)P) accumulation on phagosome membranes in CCC deficient states, leading to impaired phagosome function. Collectively, our findings uncover a previously unknown role for the CCC complex in innate immune defense.